

Remarks

Claims 1 to 42 are presently pending in this patent application. In view of the following remarks, reconsideration and withdrawal of the requirement for restriction ("the Requirement") are requested respectfully.

Discussion of the Requirement and Election

The Action requires applicants to select one of the following three groups of allegedly patentably distinct inventions for examination.


- I. Claims 1 to 36, drawn to a compound of formula (I) and a pharmaceutical composition containing a compound of formula (I); and
- II. Claim 37 to 42, drawn to a method of use of a compound of formula (I).

Applicants elect the claims of Group I. Because the elected Group I claims include compound claims and the non-elected Group II claims are directed to methods of using such compounds, Applicants request that if the claims of elected Group I are allowed, the claims of non-elected Groups II be rejoined in accordance with MPEP §821.04. Further, applicants reserve the right to pursue any subject matter that remains after the prosecution of the present in a later-field divisional application.

The Action also includes a request to elect a species of the compounds represented by formula (I). In this regard, Applicants elect as the species the compound 3-(pyrid-4-yl)-3-(((2-*o*-tolylamino-benzoxazol-6-yl)-acetyl)-1,2,3,4-tetrahydro-isoquinolin-7-yl)-propanoic acid that is described in Example 1(e) at page 44 of the specification and is represented by the following formula.

USCA2425 US CNT


PATENT



The Commissioner is hereby authorized to charge the fee required and any additional fees that may be needed to Deposit Account No. 18-1982 in the name of Aventis Pharmaceuticals Inc.

Respectfully submitted,

Dated: May 9, 2006


Joseph D. Rossi
Registration No. 47,038
Attorney for Applicants

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone: 908-231-3410
Telefax: 908-231-2626

USCA2425 US CNT